Clinical Trials

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03191149 2026-03-18

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

46 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02971501 2026-03-17

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

7 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06618287 2026-03-17

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

416 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT06525246 2026-03-13

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Phase 1 Completed

78 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03381274 2026-03-11

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

43 enrolled 30 charts

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06194448 2026-03-06

NEOLA

76 enrolled

Phase 1 Active not recruiting

Lung Neoplasms

NCT05166616 2026-03-05

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

8 enrolled

Lung Neoplasms

NCT05401110 2026-03-04

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05526755 2026-03-04

TARGET

188 enrolled

Stage II-IIIB Non-small Cell Lung Carcinoma

NCT06417814 2026-03-02

TROPION-Lung15

Phase 3 Recruiting

744 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-02-27

LAURA

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT04606771 2026-02-27

CoC

30 enrolled 20 charts

GastrointestinalHead & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05647122 2026-02-20

EGRET

Phase 1 Recruiting

403 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms

NCT06741085 2026-02-18

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

56 enrolled

Non Small Cell Lung Cancer Metastatic

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase 3 Recruiting

380 enrolled

NSCLC Patients With Brain Metastasis

NCT07379476 2026-02-12

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

64 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03778229 2026-02-10

SAVANNAH

367 enrolled 32 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT07375316 2026-02-10

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02917993 2026-02-09

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Phase 1/2 Completed

59 enrolled

Carcinoma, Non-Small-Cell Lung, Inhibition, Psychological, Lung Neoplasms, Neoplasm Metastasis

NCT03133546 2026-02-06

BOOSTER

Phase 2 Completed

155 enrolled 23 charts

Non Small Cell Lung Cancer Metastatic

NCT04487080 2026-02-04

MARIPOSA

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04184921 2026-02-03

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Phase 2 Completed

216 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07376382 2026-02-02

SYNSTAR-02

450 enrolled

Phase 1 Active not recruiting

NSCLC

NCT02143466 2026-01-30

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Advanced Non Small Cell Lung Cancer

NCT05546866 2026-01-27

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

51 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05816252 2026-01-27

MK-2870-003

356 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04486833 2026-01-21

Acclaim-1

Phase 1/2 Recruiting

158 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04743505 2026-01-20

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05089916 2026-01-14

ROSE

42 enrolled

NSCLC

NCT05624996 2026-01-14

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

474 enrolled

Lung Neoplasms

NCT04765059 2026-01-13

COMPEL

98 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT04769388 2026-01-12

FLAME

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05120349 2026-01-12

ADAURA2

390 enrolled

674 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT02442349 2026-01-09

AURA17

Phase 2 Completed

171 enrolled 14 charts

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07329322 2026-01-09

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07323641 2026-01-07

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT02511106 2026-01-05

ADAURA

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT07315113 2026-01-02

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03410043 2025-12-26

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

173 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07079475 2025-12-24

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Phase 1/2 Recruiting

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03810807 2025-12-23

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1 Completed

22 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07295821 2025-12-22

NSCLC

Phase 1/2 Not yet recruiting

Lung Neoplasms

NCT07153055 2025-12-18

LOTS

16 enrolled

Phase 1/2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07285148 2025-12-16

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

253 enrolled